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Abstract: Epidermal differentiation complex (EDC) comprises a number of genes associated with human skin 
diseases including psoriasis, atopic dermatitis and hyperkeratosis. These genes have also been linked to nume-
rous cancers, among them skin, gastric, colorectal, lung, ovarian and renal carcinomas. The involvement of EDC 
components encoding S100 proteins, small proline-rich proteins (SPRRs) and other genes in the tumorigenesis 
of head and neck squamous cell cancer (HNSCC) has been previously suggested. The aim of the study was to 
systematically analyze the expression of EDC components on the transcript level in HNSCC. Tissue specimens 
from 93 patients with HNC of oral cavity and 87 samples from adjacent or distant grossly normal oral mucosa 
were analyzed. 48 samples (24 tumor and 24 corresponding surrounding tissue) were hybridized to Affymetrix 
GeneChip Human 1.0 ST Arrays. For validation by quantitative real-time PCR (QPCR) the total RNA from all 
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180 samples collected in the study was analyzed with Real-Time PCR system and fluorescent amplicon specific-
-probes. Additional set of samples from 14 patients with laryngeal carcinoma previously obtained by HG-U133 
Plus 2.0 microarray was also included in the analyses. The expression of analyzed EDC genes was heteroge-
neous. Two transcripts (S100A1 and S100A4) were significantly down-regulated in oral cancer when compared 
to normal mucosa (0.69 and 0.36-fold change, respectively), showing an opposite pattern of expression to the 
remaining S100 genes. Significant up-regulation in tumors was found for S100A11, S100A7, LCE3D, S100A3 and 
S100A2 genes. The increased expression of S100A7 was subsequently validated by QPCR, confirming significant 
differences. The remaining EDC genes, including all encoding SPRR molecules, did not show any differences 
between oral cancer and normal mucosa. The observed differences were also assessed in the independent set 
of laryngeal cancer samples, confirming the role of S100A3 and LCE3D transcripts in HNC. In HNC of oral 
cavity only one family of EDC genes (S100 proteins) showed significant cancer-related differences. A number 
of other transcripts which showed altered expression in HNC require further validation. (Folia Histochemica et 
Cytobiologica 2014, Vol. 52, No. 2, 79–89)
Key words: HNSCC; oral SCC; laryngeal cancer; epidermal differentiation complex; S100 genes; LCE3D; 
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Introduction
Epidermal differentiation complex (EDC) comprises 
many genes clustered on chromosomal human region 
lq21 and coding for proteins involved in late differen-
tiation of epithelial cells. These genes are divided into 
three families encoding: cornified cell envelope (CE) 
precursors (involucrin, loricrin, small proline-rich 
proteins — SPRRs and the “late cornified envelope” 
proteins, LCEs), calcium-binding proteins (S100) with 
EF-hand domains, and “fused gene” proteins (SFTPs, 
‘S100 Fused Type proteins’) involving filaggrin, filag-
grin-2, repetin, trichohyalin, cornulin and hornerin [1]. 
Epidermal differentiation molecules are important 
especially for a plethora of skin diseases [1]. They may 
also constitute an important feature differentiating 
squamous cell carcinomas (SCC) from other types 
of cancer, e.g. adenocarcinomas, despite the fact that 
the epidermal differentiation is also an important 
mechanism in adenocarcinoma [2].
More than 10 years ago Zucchini et al. provided an 
early insight into the expression profile of EDC genes 
in normal and cancer cells by DNA macroarray [3]. 
The largest and best known family of EDC genes are 
these which encode S100 proteins. 21 of human S100 
genes are clustered at chromosomal region frequently 
deleted, translocated or duplicated in epithelial and 
soft-tissue tumors [4]. It is believed that each member 
of the gene S100 family plays a role in tumorigenesis 
and mechanisms of metastases, however, their precise 
role in the development and promotion of cancer 
is largely unclear. It was shown that S100 proteins 
were involved in tumor metastasis by interacting with 
matrix metalloproteinases, cytoskeletal proteins, p53, 
Jab 1, Cox-2 and BRCA1 proteins [5]. S100B, one 
of the best-studied proteins (located outside EDC 
complex on chromosome 21q22.3), is currently used 
as a biomarker for melanoma, reflecting tumor bur-
den and correlating with overall survival [4]. S1004A 
protein is considered another potential key player in 
tumor progression and metastasis [6, 7]. However, 
S100 proteins can also play an anti-oncogenic role in 
head and neck cancer (HNC) [8].
Late cornified envelope (LCE) proteins, belonging 
to cornified envelope precursors, are encoded by 
LCE genes organized into three linked subclusters 
on 1q21. They are expressed primarily in skin and are 
regulated by UV irradiation and calcium [9]. Their 
expression is altered in skin diseases — psoriasis and 
atopic dermatitis [1].
Increasing number of reports suggest the role of S100 
proteins [10–12], SPRRs [13] and other EDC genes in 
HNC, including laryngeal and oral carcinomas. One of 
the earliest studies of expression profiling in head and 
neck squamous cell carcinoma (HNSCC) was carried out 
in hypopharyngeal cancer samples against histologically 
normal tissue [14]. 1q21 locus overexpression was noted 
as a clear feature of gene expression in these tumors. 
Hudson et al. also suggested potential role of EDC 
complex genes in HNSCC in their microarray study [15]. 
The aim of our study was to analyze systematically the 
expression of the EDC genes on the transcript level in 
head and neck cancer of oral cavity.
Material and methods
Patients. Tissue specimens were collected retrospectively 
from 93 patients with HNC of oral cavity, operated on in 
the Department of Oncological Surgery, Maria Sklodowska- 
-Curie Memorial Cancer Center and Institute of Oncology 
(Gliwice, Poland) in years 2007–2012. Intraoperative tumor 
specimens were available from all patients. Additionally, 
87 samples from adjacent or distant grossly normal oral 
mucosa were collected (1–3 per patient). The study was 
approved by a local ethics committee and all patients gave 
the informed consent.
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Among 24 subjects in whom the detailed microarray 
examination was carried out there were 79% of male pa-
tients, median age 57 years. In that group there were 4% of 
patients with grade 1 tumor, 66% G2 and 30% G3 subjects.
Histopathological assessments were carried out in a typical 
manner: specimens were fixed in 10% buffered formalin and 
embedded in paraffin blocks, cut into ultra-thin paraffin sections 
3–4 µm thick and stained with hematoxylin and eosin (HE). 
Tissue fragments, weighting about 70 µg, adjacent to fragments 
sent for histological examination were placed on dry ice imme-
diately after collection and stored deep frozen at −80°C.
Additionally, data from 14 patients with squamous cell la-
ryngeal carcinoma, diagnosed and surgically treated between 
2005 and 2007 in the Laryngology Department of the Silesian 
Medical University in Katowice, Poland, previously assessed 
in our laboratory by microarray profiling (as described by 
Markowski et al., 2009), were included in the analysis [16].
RNA isolation. RNA was extracted from fresh frozen tissues 
using a standard RNeasy Micro Kit protocol including a 
digestion step with RNase-free DNase I (Qiagen). The qu-
antity and quality control was performed using NanoDrop 
1000 spectrophotometer (Thermo Scientific) and RNA 6000 
Nano LabChip kit (Agilent Technologies). Total RNAs RIN 
values were between 6.8 and 9.5.
Microarray analysis of gene expression. 500 ng of total RNA 
from 48 tissue fragments (24 tumor and 24 corresponding 
surrounding tissues) were used for the microarray experi-
ment (Affymetrix GeneChip Human 1.0 ST Arrays). The 
cDNA was synthesized, fragmented and labeled with biotin 
using the Ambion WT Expression Kit (Life Technologies) 
following the procedure described in the Ambion WT 
Expression Protocol. The arrays were incubated in a Ge-
neChip Hybridization Oven 640 (Affymetrix), washed and 
stained on a GeneChip Fluidics Station 450 (Affymetrix) 
using the Hybridization Wash and Stain Kit (Affymetrix) 
and the Fluidics Procedure FS450_0007. The arrays were 
processed with a GeneChip Scanner 3000 (Affymetrix).
For laryngeal cancer samples, older generation high 
density microarrays, Human Genome U 133 Plus 2.0 (Af-
fymetrix) were used. 
Real-Time Quantitative RT-PCR (QPCR). Total RNA from 
180 fresh frozen oral cavity cancer samples (all specimens 
collected in the study) was used for QPCR validation. Re-
verse transcription was performed using Qiagen Omniscript 
RT Kit. The input RNA for each sample was 200 ng in 
a final volume of 20 µL. All samples were diluted 10 times 
prior to QPCR. Reactions were performed in duplicates on 
384-well plates using 7900HT Fast Real-Time PCR system 
(Life Technologies). The QPCR conditions consisted of 
a first step at 50°C (2 min; activation and incubation with 
AmpErase UNG) and 95°C (10 min; activation AmpliTaq 
Gold polymerase), followed by 40 cycles of amplification 
(95°C, 15 s; 60°C, 1 min). Each reaction contained 10 µl of 
Taqman Universal Mastermix (Life Technologies), 200 nM 
of each primer, 2.8 µl RNasy free water and 5 µl of diluted 
cDNA template. For amplicon design we used the Roche 
Universal Probe Library (Table 1) following general condi-
tions: 1) an amplified sequence for all transcripts covered by 
the microarray probe, 2) amplicon unique to human tran-
scriptomic database (confirmed by BLAST), 3) no known 
single nucleotide polymorphisms (SNPs) in any of primers 
or probe sequence (confirmed by BLAST SNP). Standard 
curve was performed for each amplicon of the 8 duplicate 
concentrations (1000 ng, 500 ng, 200 ng, 100 ng, 40 ng, 20 ng, 
8 ng, and 2 ng of total RNA). The linear regression slope of 
the standard curve indicated amplification efficiency. For 
normalization of QPCR data three transcripts were chosen 
as reference: EIF3S10, HADHA and UBE2D2, based on 
previously carried out QPCR analysis of SPRR gene expres-
sion in skin [17]. The normalization factor was obtained 
using the GeNorm applet for Microsoft Excel, based on 
the three reference genes tested. After quality assessment, 
91 tumor samples and 84 samples of normal mucosa were 
used for final analysis.
Data analysis. Microarray data were pre-processed by RMA 
algorithm, using Bioconductor 1.5 packages. Expression data 
were transferred to BRB Array Tools 4.3.2 (developed by 
Dr. Richard Simon and BRB Array Development Team) 
and subset of genes located in 1q21 chromosomal region 
was selected. Among the genes of EDC cluster represented 
by probe-sets on GeneChip Human 1.0ST microarray there 
Table 1. QPCR amplicon design
Gene Fluorescent probe sequence Forward primer sequence Reverse primer sequence Efficiency
S100A7 cttcccca ctgctgacgatgatgaagga cgaggtaatttgtgcccttt 1.86
S100A9 gacctgga gtgcgaaaagatctgcaaaa tcagctgcttgtctgcattt 1.81
SPRR1A ctccagca caccccaaagtgcctgag ttctgcttggtcttctgctg 1.80
SPRR1B cagctccc gagagacttaagatgaaagcaaatga tgaaagtgaatttaatgggggta 1.86
Amplicons were designed with Universal Probe Library locked-nucleic acid probes, as described in Methods section
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were the following transcripts: CGN, LCE2B, IVL, SPR-
R1A, SPRR3, SPRR1B, LOR, S100A9, S100A1, S100A10, 
S100A11, CRNN, LCE3D, SPRR2D, SPRR2B, SPRR2, 
SPRR2E, SPRR2G, S100A12, S100A8, S100A7, S100A4, 
S100A3, S100A2, S100A16, SPRR2F. Within this limited list 
the statistically significant transcripts were identified by a 
supervised analysis using random variance t-test with False 
Discovery Rate estimation according to Benjamini-Ho-
chberg algorithm. False Discovery Rate below 0.1 (10%) was 
deemed significant. Microarray data for selected transcripts 
were also exported out to JMP Genomics to carry on the 
Principal Component Analysis. Normalized QPCR data 
were assessed by non-parametric U Mann-Whitney test.
Results
Analysis of 1q21 epidermal differentiation  
genes in oral cancer 
Using microarray technology we analyzed expression 
of all EDC 1q21 genes in the panel of 24 oral SCC and 
compared the expression to the corresponding normal 
mucosa specimens from the same individuals. First, an 
unsupervised Principal Component Analysis (PCA) 
was carried out on the full dataset. The gene expres-
sion patterns within first two principal components 
are summarized in Figure 1. It can be clearly observed 
that two transcripts (S100A1 and S100A4) show an 
opposite pattern of expression to the remaining EDC 
genes. Both genes are highly significantly down-re-
gulated in oral cancer when compared to adjacent 
normal mucosa (Figure 2A, Table 2). Both genes show 
similar level of expression in normal mucosa, while 
the down-regulation is higher for S100A1 (approx. 
3-fold decrease) in comparison to S100A4 (30% lower 
expression in cancer). It is to be noted that both genes 
exhibit lower expression in normal oral mucosa than 
the remaining S100 genes. The PCA also revealed 
that four genes: S100A7, loricrin and two late corni-
fied envelope genes (LCE2B and 3D) show slightly 
divergent profile in comparison to the remaining set of 
relatively uniform transcripts (Figure 1). In microar-
ray analysis, S100A7 and LCE3D showed significant 
differences in gene expression (Figure 2B, Table 2), 
both genes being up-regulated in cancer tissues, 
while for LCE2B and LOR no significant differences 
were confirmed. Within the remaining genes highly 
significant differences were also noted for S100A11, 
while S100A3, S100A2 (up-regulated in cancer) and 
cingulin (slightly down-regulated in cancer) showed 
a trend towards difference. Up-regulation of S100A7 
and LCE3D was almost fourfold in malignant tissue, 
while all remaining genes showed 37–57% increase 
in comparison to adjacent normal mucosa (Table 2).
Analysis of EDC in an independent set  
of laryngeal cancer samples 
The expression of EDC genes was analyzed indepen-
dently in the group of laryngeal cancers vs. normal 
mucosa samples. Three genes found to be changed 
in oral cancer (S100A3, LCE3D and CGN) similarly 
showed significant differences in laryngeal cancer, 
with comparable fold-change ratios (Table 3). All 
other differentiating genes in oral cancer showed no 
significant differences in laryngeal cancer set (FDR 
> 10%). Three other transcripts, not differentially 
expressed in oral cancer, were significantly changed in 
laryngeal cancer (FDR < 10%), namely SPRR2G (up
-regulated in cancer more than eight-fold), CRNN and 
S100A10 (both down-regulated in cancer; Table 3). 
Validation by quantitative real time PCR 
For the validation study, we selected S100A7, a gene 
of high significance in oral cancer (ranked # 3 within 
S100 transcripts in microarray analysis), to provide 
a confirmation of positive results and three genes of 
no significance to provide a confirmation of negative 
findings in the much larger population. The QPCR 
results showed a highly significant difference for 
S100A7 gene while no differences were observed 
for the remaining genes (Figure 3), confirming the 
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Figure 1. Principal component analysis of gene expression 
values in the whole dataset or oral cancer specimens and 
oral mucosa. First two principal components are depicted 
on axes X and Y
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significance of our findings using an independent 
method in much larger dataset. Median of S100A7 
expression in normal mucosa group was 0.07 arbi-
trary units, in oral cancer median was 0.29 units, 
the ratio of geometric means between tumor and 
normal samples was 5.4. These results confirmed 
the difference observed in microarray study (3.9-fold 
increase in cancer). 
Figure 2. Gene expression measurement by microarray study for selected down-regulated (A) and up-regulated genes (B). 
Significant differences were observed for S100A1, S100A4, S100A7 and LCE3D (FDR < 5%). On Y axis the log2-trans-
formed expression of genes from microarray analysis is shown (arbitrary units). Vertical line denotes the grand mean 
expression value in both groups
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Summary of the results 
In two datasets of head and neck cancer (oral ca 
and laryngeal ca) we consistently observed an over- 
expression of three genes — S100A3, LCE3D and 
CGN. Moreover, in oral cancer we found an increased 
expression of the other S100 transcripts, one of them, 
S100A7, was validated in a larger group of patients by 
independent method. Two S100 genes — S100A1 and 
S100A4 showed highly significant decrease in gene 
expression in oral cancer. In oral cancer, we found 
no differences in SPRR genes expression nor other 
EDC genes, e.g. for involucrin.
Discussion 
In the current study it was the expression of S100 
genes which appeared as the most significant tumor- 
Table 2. Expression of EDC genes in oral cancer (microarray study)
Symbol or full name of the gene FDR Gene expression in mucosa Gene expression in oral cancer Fold-change
S100 calcium binding proteins
S100A1 2.33E-06** 91.95 32.84 0.36
S100A4 4.80E-05** 96.54 67.05 0.69
S100A7 0.0058** 224.98 868.64 3.86
S100A11 0.00924** 2283.07 3468.52 1.52
S100A3 0.0559* 59.34 81.23 1.37
S100A2 0.0947* 258.45 404.53 1.57
S100A12 0.162 155.3 268.64 1.73
S100A10 0.459 3359.25 3712.7 1.11
S100A9 0.900 2644.01 2405.17 0.91
S100A16 0.975 1758.79 1776.2 1.01
S100A8 0.975 6329.6 6197.08 0.98
Other genes
LCE3D  
(late cornified envelope 3D)
0.00699** 273.69 1035.47 3.78
CGN (cingulin) 0.095* 63.01 52.76 0.84
CRNN (cornulin) 0.207 1896.74 779.82 0.41
LCE2B  
(late cornified envelope 2B)
0.273 109.46 159.73 1.46
IVL (involucrin) 0.736 441.03 525.26 1.19
LOR (loricrin) 0.777 48.57 54.23 1.12
Small proline-rich proteins
SPRR3 0.187 3809.31 1790.96 0.47
SPRR2B 0.404 130.63 218.72 1.67
SPRR1B 0.408 1889.66 2716.83 1.44
SPRR2E 0.408 689.2 1129.1 1.64
SPRR2G 0.43 2023.99 2816.68 1.39
SPRR2D 0.451 58.68 79.9 1.36
SPRR2F 0.479 2297.76 3018.76 1.31
SPRR2B 0.705 232.82 319.84 1.37
SPRR2A 0.959 2718.04 2930.41 1.08
SPRR2G 0.959 1387.42 1329.25 0.96
SPRR1A 0.975 3402.43 3487.3 1.02
Gene expression values are presented as geometric means, the fold-change is also presented  
*False discovery rate (FDR) was deemed significant if within 1–10% (0.01–0.1), and **highly significant if FDR < 0.01 (1%)
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-normal difference within all analyzed EDC genes, 
based on the comparison between oral cavity SCCs 
to matching normal mucosa. There are numerous 
reports confirming S100 genes alterations in many 
tumors and some of the changes were suggested as 
markers of tumor progression [18]. The potential 
Table 3. Expression of EDC genes in laryngeal cancer (microarray study)
Symbol FDR Gene expression in mucosa Gene expression in laryngeal cancer Fold-change
Up-regulated in cancer
SPRR2G 0.00194 19.47 161.05 8.27
S100A3 0.0713§ 26.23 43.29 1.65
LCE3D 0.0852§ 62.43 265.26 4.25
Down-regulated in cancer
CGN 0.0182§ 54.63 30.45 0.56
CRNN 0.0198 1533.34 96.99 0.06
S100A10 0.0478 171.53 81.96 0.48
Gene expression values are presented as geometric mean values. Only transcripts with FDR < 0.1 (10%) are shown  
§Results significant also in the oral cancer microarray analysis (Table 2)
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Figure 3. QPCR validation of S100A7 down-regulation in oral cancer. Y axis presents normalized gene expression values 
as measured by QPCR (arbitrary units). Differences are significant for S100A7 (p < 0.05, U Mann-Whitney test). Vertical 
line denotes grand mean in both groups
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prognostic significance of S100 proteins was demon-
strated by Albuquerque et al. who associated S100 
immunohistochemical (IHC) expression with the 
histological grading in oral cancer [19] and stressed 
the relative heterogeneity related to the anatomical 
location of the tumor. 
In our analysis we found significantly decreased 
expression of two S100 proteins: S100A1 and S100A4 
in oral SCC. In previous studies S100A1 gene expres-
sion, determined by microarray, QPCR and Western 
blot analyses, was shown to be relatively low in most 
normal tissues, however, it was up-regulated in 
kidney, ovarian and skin cancers [20]. Moreover, it 
may constitute a negative prognostic factor in some 
cancers — e.g. in patients with endometrioid subtype 
of ovarian and endometrial carcinoma — DeRycke 
et al. demonstrated in this setting a negative corre-
lation between S100A1 expression and relapse free 
survival time [20]. We also observed a relatively low 
S100A1 expression in normal oral mucosa, with even 
more reduced expression in oral tumors, suggesting 
tissue-specific differences of gene regulation.
S100A4 (metastatin) is known to be expressed in 
nervous system, where it is probably involved in neu-
rite extension. It is over-expressed in many tumors, 
among them breast, lung, colorectal, gastric, prostate, 
ovarian, and pancreatic cancers as well as malignant 
melanoma [21]. It was demonstrated by Grigorian 
et al. that, by interaction with p53, S100A4 inhibits 
p53-mediated tumor suppression [22]. Combined 
aberrant expression of E-cadherin and S100A4, but 
not b-catenin was associated with disease-free survival 
and overall survival in colorectal cancer patients [23]. 
This association could also be a mechanism of regu-
lation of angiogenesis and tumor invasion, as shown 
in thyroid cancer [24]. S100A4 levels in pancreatic 
cancer were suggested to predict radioresistance [25]. 
Although originally S100A4 role has been identified in 
metastatic breast cancer cells [26], it has been recently 
suggested that S100A4 expression may be induced by 
the tumor microenvironment also in oral cancer [27].
There are published data available showing the 
possible association between S100 proteins and head 
and neck cancer. The altered expression of various 
S100 proteins was reported in primary and metastatic 
laryngeal carcinomas [28] and epithelial tumors of the 
skin [29]. S100A4 was confirmed to regulate E-cadherin 
expression in oral SCC cell lines [30], and its expression 
was correlated with invasion and metastasis [31]. It was 
shown to mediate epithelial-mesenchymal transition 
in HNSCC and was associated with stem-cell like 
phenotype (S100A4 knockdown reduced self-renewal 
and stemness of cells, while S100A4 over-expression 
enhanced their stem cell properties) [32].
In head and neck cancer higher expression of 
S100A4 assessed by immunohistochemistry was repor-
ted by de Oliveira et al. [18] in patients with metastatic 
lymph nodes as compared with the non-metastasizing 
tumors. The expression of S100A4 was analyzed 
parallel to endoglin, a protein probably regulated by 
S100A4, which also showed similar pattern of expres-
sion. In our study we observed a significant down-re-
gulation of S100A4 gene expression in oral primary 
SCC vs. matched adjacent normal tissue. Similarly 
to S100A1 the expression of S100A4 gene observed 
in our study on transcript level was lower in normal 
mucosa, when compared to other S100 genes. Its de-
crease in cancer requires further analysis to check if 
this is associated with functional effects. Interestingly, 
Oliveira et al. showed that lower expression of S100A4 
in primary non-metastatic HNSCC samples was not 
associated with altered methylation status of its gene 
as compared to metastatic tissue [18]. 
Other S100 proteins found by us to be up-regu-
lated in HNSCC samples have also been linked to 
cancer biology. S100A7 (psoriasin) is a DNA dama-
ge-inducible gene [33], which is primarily involved in 
chemotaxis of inflammatory cells. It is up-regulated 
in breast, bladder and skin cancers [34]. According 
to Emberley et al. S100A7 protein expression cor-
relates with aggressive course and overall survival in 
breast cancer [26]. An increased nuclear localization 
of S100A7 was associated with poorer prognosis in 
HNSCC [35]. Winter et al. assessed the transcript 
expression of S100A7 in oral lesions and confirmed 
the up-regulation of this gene [36]. Our data support 
these observations and show S100A7 to be the most 
significantly over-expressed gene within the EDC 
cluster with observed fold change 3.9 and 5.4 (by 
microarray and QPCR, respectively).
We have also noted a slight (1.5-fold change) but 
significant up-regulation of S100A11 in cancer tissues. 
Anania et al. found that in papillary thyroid cancer 
an over-expression of S100A11 may contribute to 
the malignant phenotype [37], moreover, the role of 
S100-positive dendritic cells in this context has been 
recently discussed [38]. In laryngeal cancer S100A11 
gene was over-expressed both on mRNA and protein 
level and its expression was associated with a migra-
tory capacity [39].
In the current study we observed a borderline 
significant up-regulation of S100A2 and S100A3 in 
comparison to normal mucosa (fold change 1.6 and 
1.4, respectively). The role of S100A2 in carcinogene-
sis has been previously discussed [40]. In contrast to 
our data, S100A2 was down-regulated in oral cancer 
cell lines as identified by mRNA profiling analysis 
and proposed a potential marker of poor prognosis 
87Epidermal differentiation complex in head and neck cancer
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2014
10.5603/FHC.2014.0018
www.fhc.viamedica.pl
in early stage oral cancer since Tsai et al. observed 
significant correlation between reduced nuclear levels 
of S100A2 protein and shorter disease-free survival 
in early stage oral cancer patients [10]. Low protein 
level of S100A2 was associated with lymph node me-
tastases in stage I–II oral cavity SCC [11]. A higher 
incidence of late cervical metastasis was observed in 
S100A2 negative tumors than in those with S100A2 
positive cancers. Moreover, in multivariate analysis 
S100A2 expression was the only independent factor 
for late cervical metastases [11]. Low expression of 
this protein was associated with worse outcome in 
pancreatic cancer after adjuvant treatment [41].
An aberrant S100A3 gene expression has not 
been previously reported for HNSCC. However, 
chromosomal amplifications involving S100A3 were 
found in esophageal SCC after exposure to tobacco 
and betel quid [42]. Furthermore, S100A3 up-regu-
lation was shown in colorectal [43] and bladder [44] 
cancers in addition to gastric cancer where S100A3 
over-expression correlated with tumor differentiation 
and TNM stage [45].
Attention should also be focused on S100A8/ 
/S100A9 (calprotectin), which is a toll-like receptor 4 
agonist and is considered a proinflammatory and mali-
gnancy-stimulating factor [46]. S100A8/A9 molecules 
have been associated with epithelial-mesenchymal 
transition in breast carcinoma cells [47], as well as with 
the progression of colorectal carcinoma [48]. S100A8 
expression has been analyzed in HNSCC and various 
degrees of premalignant lesions, as well as in serum 
of HNSCC patients [49]. In fact, S100A8/A9 has been 
regarded as a Janus-faced molecule in cancer therapy 
and carcinogenesis [50]. In the current study, we did 
not observe any differences on S100A8/A9 transcript 
levels between cancer and normal oral tissues.
In our study not all S100 transcripts were analyzed. 
E.g., decreased expression of S100A6 (calcyclin) in 
oral SCC [51] was also previously described, that gene 
was confirmed to be regulated on the epigenetic level 
[52, 53]. Another gene, S100A14 may regulate the 
invasiveness of HNSCC by influencing the expression 
of matrix metalloproteinases [54], it may interact with 
S100A16 [55].
Among other 1q21 genes we observed an up-regu-
lation of LCE3D. This gene has not been previously 
reported to be of increased expression in cancer 
tissues. Another, previously not thoroughly analyzed 
gene is cingulin, also observed as up-regulated in 
the current study. It is a potentially important adhe-
sion molecule, currently thought to be regulated by 
EphrinB signaling [56, 57].
Small proline-rich proteins, like SPRR2A were 
found to be among the most highly up-regulated genes 
in many non-squamous, stressed and remodeling bar-
rier epithelia [58]. Based on these data we expected 
to see their aberrant expression in HNSCC. Although 
the SPRR gene cluster showed some degree of de-
regulation, the observed changes of expression were 
without statistical significance in our study. Despite 
being within the same 1q21 locus, SPRRs showed 
fewer differences between tumor and normal tissues 
than S100 genes. Therefore, we were not able to 
confirm in non-keratinizing oral carcinoma observa-
tions made in skin cancer by de Heller-Milev et al. 
(immunohistochemistry and Northern blotting) [59]. 
However, such a trend was observed in laryngeal can-
cer since we observed aberrant SPRR2G expression. 
It has to be stressed that the proteins originating 
from the complex structure of skin layers and regu-
lating its keratinization may behave differently in 
various contexts [60, 61]. When we compared our data 
with the analysis of Hudson et al., who suggested that 
coordinated over-expression of EDC genes is a hall-
mark of skin squamous cell carcinoma, we reached 
similar global conclusions [15]. The most over-expres-
sed gene in their study was S100A12, and other eight 
S100 genes were over-expressed. Moreover, they 
found over-expression of five SPRR genes, involucrin 
and LCE3D gene. For LCE3D over-expression the 
results are in perfect agreement with our conclusion. 
The global over-expression of S100 genes is also in 
concordance with our observations, although our set 
of oral cancer patients provides strong suggestion 
that some S100 transcripts (S100A1/S100A4) may be 
down-regulated. 
Thiel et al. attempted to analyze all differentially 
expressed proteins in oral squamous cell carcinoma 
by proteomic techniques (MALDI-TOF mass spectro-
metry) [62]. Significant expression and most notable 
differences were reported for involucrin and stratifin. 
The other authors also found differences in gene 
expression of stratifin and involucrin in addition to 
S100 calcium binding proteins [63]. However, we did 
not observe any differential expression of involucrin 
and stratifin transcripts in the current study. 
At the moment it is not clear whether EDC genes 
are associated with any prognostic or predictive signi-
ficance. When different biological parameters were 
analyzed in the context of clinical data in patients 
with oral tongue carcinoma stage I and II treated 
by intraoral excision only, it was found that mainly 
clinical parameters and E-cadherin expression were 
predictive of survival [64]. Other widely analyzed 
biological parameters like e.g. laminin [65, 66] did not 
reveal statistical significance. 
In summary, coordinated over-expression of some 
epithelial differentiation complex genes, mainly from 
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S100 family, seems to be a constitutive feature of 
head and neck cancer. The biological and clinical 
importance of these findings warrants further study.
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